#JPM23: This is how we cure can­cer

Cur­ing can­cer, or find­ing new ways to achieve cu­ra­tive progress, ex­tend­ing lives, has be­come a hotbed of ac­tiv­i­ty in bio­phar­ma. End­points Ed­i­tor-in-Chief John Car­roll sat down at JP Mor­gan with a group of in­dus­try ex­perts work­ing on that. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

This is a sub­ject that I’ve been cov­er­ing for­ev­er, and I seem to un­der­stand less and less what’s go­ing on as I go deep­er and deep­er in­to what’s hap­pen­ing. So I’ve brought to­geth­er five great ex­perts in the field to talk about one of the most im­por­tant trends in re­search and de­vel­op­ment to­day, which is where are we go­ing to find the very big trans­for­ma­tion­al ther­a­pies in the near term that are go­ing to make some sig­nif­i­cant dif­fer­ences to pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.